SWOG clinical trial number
SWOG-8609

VM-26 (Teniposide) Single Drug Treatment for Extensive Small Cell Lung Cancer

Closed
Phase
Accrual
90%
Published
Abbreviated Title
VM-26 (Teniposide) Single Drug Treatment for Extensive Small Cell Lung Cancer
Activated
09/15/1988
Closed
11/15/1990

Research committees

Lung Cancer

Publication Information Expand/Collapse

1997

Teniposide (VM-26) as a single drug treatment for patientss with extensive small cell lung carcinoma. A Phase II study of the Southwest Oncology Group.

PN Grozea;JJ Crowley;VA Canfield;L Kingsbury;SW Ross;GS Beltran;LR Laufman;GR Weiss;RB Livingston Cancer 80(6):1029-1033

1994

SWOG 8609 - a phase II trial of teniposide (VM-26) as therapy for extensive small cell lung cancer (SCLC)

V Canfield;P Grozea;J Crowley;R Livingston Lung Cancer 11(Suppl.1):102(#389)

Other Clinical Trials

SWOG Clinical Trial Number
A082302

EVALUATING ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB AND HYALURONIDASE-TQJS TO PREVENT RECURRENCE IN STAGE I NON-SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III TRIAL (AASI-NSCLC)
Research Committee(s)
Lung Cancer
Activated
03/02/2027
Open
SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
2%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase